Cancer Vaccine Data Sends Shares Up 156%, Then $150M Offering Cools the Rally
SLS has more than doubled off its 52-week low of $1.39 on elevated volume (14× avg).
Summary
SELLAS shares jumped 156% Tuesday, the biggest single-day gain since 2020, after the Phase 3 REGAL trial of galinpepimut-S met its primary overall survival endpoint in second-remission AML. The vaccine cut the risk of death by 41% versus best available treatment, with median overall survival of 24 months against less than 15 months. The stock was up as much as 233% intraday before closing well off that high. The company then launched a $150 million underwritten common stock offering through JPMorgan and TD Cowen, and shares fell 12% in extended trading. Short interest climbed to 29% of the free float after the surge, so a crowded bearish base now sits against a stock that just cleared its binary event. The offering price and terms will set the near-term trading level; the 424B5 prospectus filed Tuesday night is the document to read for the discount.
At the time of this announcement, SLS was trading at $17.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.39 to $24.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: CNBC TV18.